<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03646123</url>
  </required_header>
  <id_info>
    <org_study_id>SGN35-027</org_study_id>
    <nct_id>NCT03646123</nct_id>
  </id_info>
  <brief_title>Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma</brief_title>
  <official_title>Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seagen Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seagen Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will study two treatment combinations for classical Hodgkin lymphoma (cHL). This&#xD;
      trial will find out if these two treatment combinations work to treat cHL. It will also find&#xD;
      out what side effects occur. A side effect is anything the drug does besides treating cancer.&#xD;
      This study will have three parts (Parts A, B, and C).&#xD;
&#xD;
      The drugs used in Part A are a combination of targeted anticancer drug (brentuximab vedotin)&#xD;
      and three chemotherapy drugs (doxorubicin, vinblastine, and dacarbazine). These four drugs&#xD;
      are called &quot;A+AVD.&quot; Participants will be treated with granulocyte colony stimulating factor&#xD;
      (G-CSF) following every dose of A+AVD for 6 cycles of treatment (12 doses).&#xD;
&#xD;
      Part A will look at whether the A+AVD drug combination reduces the number of participants who&#xD;
      experience the side effect of febrile neutropenia. Febrile neutropenia is a very low white&#xD;
      blood cell count and a fever, which can be life threatening.&#xD;
&#xD;
      Parts B and C will use drug combination of brentuximab vedotin, plus nivolumab, doxorubicin,&#xD;
      and dacarbazine. These four drugs are called &quot;AN+AD.&quot; Parts B and C will study how well the&#xD;
      drugs work to treat cHL and what side effects they cause.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will have three parts.&#xD;
&#xD;
      Part A of the study is designed to evaluate the incidence of febrile neutropenia, efficacy,&#xD;
      and dose intensity in participants with advanced stage classical Hodgkin lymphoma (cHL)&#xD;
      receiving granulocyte colony stimulating factor primary prophylaxis (G-PP) administration&#xD;
      during treatment with frontline A+AVD. In Part A, participants will be treated with&#xD;
      granulocyte colony stimulating factor (G-CSF) following every dose of A+AVD for 6 cycles of&#xD;
      treatment. Participants will be treated using institutional standard of care practices for&#xD;
      the majority of treatment decisions.&#xD;
&#xD;
      Part B is designed to evaluate the combination of brentuximab vedotin, nivolumab,&#xD;
      doxorubicin, and dacarbazine (AN+AD) as frontline treatment in participants with advanced&#xD;
      cHL. In Part B, participants will be given AN+AD combination for 6 cycles of treatment. This&#xD;
      part of the trial will look at whether this combination of drugs is effective and tolerable&#xD;
      in participants with Stage II with bulky mediastinal disease and Stage III or IV cHL.&#xD;
&#xD;
      Part C is designed to evaluate AN+AD as frontline treatment in participants with early stage&#xD;
      cHL. In Part C, participants will be given AN+AD combination for 4 cycles of treatment. This&#xD;
      part of the trial will look at whether this combination of drugs is effective and tolerable&#xD;
      in participants with Stage I or II cHL with non-bulky mediastinal disease.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 28, 2019</start_date>
  <completion_date type="Anticipated">June 7, 2026</completion_date>
  <primary_completion_date type="Anticipated">July 7, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Febrile Neutropenia (FN) Rate (Part A)</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Proportion of patients with treatment-emergent incidence of FN.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Complete response (CR) rate (Parts B and C)</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Proportion of participants with CR at end of treatment (EOT), according to the Lymphoma Response to Immunomodulatory Therapy Criteria (LYRIC).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Primary Refractory Disease Rate (Part A)</measure>
    <time_frame>Up to 9 months</time_frame>
    <description>Proportion of participants with less than CR or relapse within 3 months of EOT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CR Rate (Part A)</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Proportion of patients with CR at EOT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician-reported Progression Free Survival (PFS) (Part A)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The physician-reporting PFS is defined as the time from start of study treatment to first documentation of progression per investigator or to death due to any cause, whichever comes first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subsequent Anticancer Therapy Utilization Rate (Part A)</measure>
    <time_frame>Up to 2.5 years</time_frame>
    <description>Proportion of patients with subsequent anticancer therapies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Dose Intensity (Part A)</measure>
    <time_frame>Up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Dose Reduction and Delays (Part A)</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Proportion of patients with dose reductions or delays related to any component of A+AVD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events (Parts B and C)</measure>
    <time_frame>Up to 7 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of laboratory abnormalities (Parts B and C)</measure>
    <time_frame>Up to 7 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR) at EOT (Parts B and C)</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>ORR is defined as the proportion of participants with CR or partial response (PR) at EOT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR) (Parts B and C)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>DOR is defined as the time from the first documentation of objective tumor response (CR or PR) to the first documentation of tumor progression per LYRIC or death, whichever comes first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of complete response (DOCR) (Parts B and C)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>DOCR is defined as the time from the first documentation of complete tumor response (CR) to the first documentation of tumor progression per LYRIC or death, whichever comes first. DOCR will only be calculated for the subgroup of subjects achieving CR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival (EFS) (Parts B and C)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>EFS is defined as the time from start of study treatment to the first documentation of objective tumor progression, death due to any cause, or receipt of subsequent anticancer therapy to treat residual or progressive disease, whichever comes first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS (Parts B and C)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>PFS is defined as the time from start of study treatment to first documentation of objective tumor progression or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) (Parts B and C)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Overall survival is defined as the time from start of study treatment to the date of death due to any cause.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>Part A: A+AVD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Brentuximab vedotin (A) plus doxorubicin (+A), vinblastine (V), and dacarbazine (D) administered by intravenous (IV) infusion in participants with advanced stage classical Hodgkin lymphoma (cHL) during each treatment cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: AN+AD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Brentuximab vedotin (A) plus nivolumab (N), doxorubicin (+A), and dacarbazine (D) administered separately by IV infusion in participants with Stage II bulky mediastinal disease and Stage III or IV cHL during each treatment cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C: AN+AD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Brentuximab vedotin (A) plus nivolumab (N), doxorubicin (+A), and dacarbazine (D) administered separately by IV infusion in participants with Stage I or II cHL with non-bulky mediastinal disease during each treatment cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>brentuximab vedotin</intervention_name>
    <description>1.2 mg/kg by IV infusion</description>
    <arm_group_label>Part A: A+AVD</arm_group_label>
    <arm_group_label>Part B: AN+AD</arm_group_label>
    <arm_group_label>Part C: AN+AD</arm_group_label>
    <other_name>Adcetris</other_name>
    <other_name>SGN-35</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin</intervention_name>
    <description>25 mg/m^2 by IV infusion</description>
    <arm_group_label>Part A: A+AVD</arm_group_label>
    <arm_group_label>Part B: AN+AD</arm_group_label>
    <arm_group_label>Part C: AN+AD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vinblastine</intervention_name>
    <description>6 mg/m^2 by IV infusion</description>
    <arm_group_label>Part A: A+AVD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dacarbazine</intervention_name>
    <description>375 mg/m^2 by IV infusion</description>
    <arm_group_label>Part A: A+AVD</arm_group_label>
    <arm_group_label>Part B: AN+AD</arm_group_label>
    <arm_group_label>Part C: AN+AD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G-CSF</intervention_name>
    <description>Granulocyte colony stimulating factor (G-CSF) primary prophylaxis administered 24-36 hours after each dose of A+AVD</description>
    <arm_group_label>Part A: A+AVD</arm_group_label>
    <other_name>filgrastim</other_name>
    <other_name>pegfilgrastim</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nivolumab</intervention_name>
    <description>240 mg by IV infusion</description>
    <arm_group_label>Part B: AN+AD</arm_group_label>
    <arm_group_label>Part C: AN+AD</arm_group_label>
    <other_name>Opdivo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Treatment-na√Øve, classic Hodgkin lymphoma (cHL) participants&#xD;
&#xD;
               -  Participants enrolling in Part A of the study must have Ann Arbor Stage III or IV&#xD;
                  disease&#xD;
&#xD;
               -  Participants enrolling in Part B of the study must have Ann Arbor Stage I or II&#xD;
                  cH: with bulky mediastinal disease, or Stage III or IV&#xD;
&#xD;
               -  Participants enrolling in Part C of the study must have Ann Arbor Stage I or II&#xD;
                  cHL without bulky disease&#xD;
&#xD;
          -  Histologically confirmed cHL according to the current World Health Organization (WHO)&#xD;
             Classification&#xD;
&#xD;
          -  Bidimensional measurable disease as documented by PET/CT or CT imaging&#xD;
&#xD;
          -  Age 12 years or older in the United States. For regions outside of the US,&#xD;
             participants must 18 years or older.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Nodular lymphocyte predominant HL&#xD;
&#xD;
          -  History of another malignancy within 3 years of the first dose of study drug or any&#xD;
             evidence of residual disease from a previously diagnosed malignancy. Exceptions are&#xD;
             malignancies with a negligible risk or metastasis or death. Participants with&#xD;
             nonmelanoma skin cancer, localized prostate cancer, or carcinoma in situ of any type&#xD;
             are not excluded if they have undergone complete resection&#xD;
&#xD;
          -  Prior immunosuppressive chemotherapy, therapeutic radiation, or any immunotherapy&#xD;
             within 4 weeks of the first study drug dose&#xD;
&#xD;
          -  Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-CTLA-4 antibody, or&#xD;
             any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint&#xD;
             pathways&#xD;
&#xD;
          -  Active cerebral/meningeal disease related to the underlying malignancy&#xD;
&#xD;
          -  Any active Grade 3 or higher viral, bacterial, or fungal infection within two weeks of&#xD;
             the first dose of study drug (Grade 3 defined by the National Cancer Institute's&#xD;
             Common Terminology Criteria for Adverse Events, NCI CTCAE Version 4.03)&#xD;
&#xD;
          -  Current therapy with other systemic anti-neoplastic or investigational agents&#xD;
&#xD;
          -  Planned consolidative radiotherapy (Parts B and C only)&#xD;
&#xD;
          -  Active interstitial lung disease that is symptomatic or may interfere with the&#xD;
             detection or management of suspected drug-related pulmonary toxicity (Parts B and C&#xD;
             only)&#xD;
&#xD;
          -  Grade 3 or higher pulmonary disease unrelated to underlying malignancy&#xD;
&#xD;
          -  Documented history of idiopathic interstitial pneumonia or diffusing capacity of the&#xD;
             lung for carbon monoxide &lt;50% predicted&#xD;
&#xD;
          -  History of a cerebral vascular event within 6 months of first dose of study drug&#xD;
&#xD;
          -  Child-Pugh B or C hepatic impairment&#xD;
&#xD;
          -  Grade 2 or higher peripheral sensory or motor neuropathy&#xD;
&#xD;
          -  Participants with acute or chronic graft-versus-host-disease (GvHD) or receiving&#xD;
             immunosuppressive therapy as treatment or as prophylaxis against GvHD&#xD;
&#xD;
          -  Previous treatment with brentuximab vedotin&#xD;
&#xD;
          -  Participants who are pregnant or breastfeeding&#xD;
&#xD;
          -  Other serious condition that would impair the participant's ability to receive or&#xD;
             tolerate the planned treatment and follow-up&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Linda Ho, MD</last_name>
    <role>Study Director</role>
    <affiliation>Seagen Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Seagen Trial Information Support</last_name>
    <phone>866-333-7436</phone>
    <email>clinicaltrials@seagen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Compassionate Care Research Group</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers - Aurora</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Gibson</last_name>
      <phone>303-418-7643</phone>
      <email>Patricia.Gibson@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>John M Burke</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado Health Memorial Hospital</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80909</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alicia Deschaine</last_name>
      <phone>719-365-5000</phone>
      <email>autumn.clemons@uchealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Alicia Deschaine</last_name>
      <phone>719-365-5000</phone>
      <email>Alicia.Deschaine@uchealth.org</email>
    </contact_backup>
    <investigator>
      <last_name>Vishal Rana</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Centers of Colorado - Denver</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benjamin George</last_name>
      <phone>303-673-1944</phone>
    </contact>
    <investigator>
      <last_name>Benjamin George</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Poudre Valley Health System (PVHS)</name>
      <address>
        <city>Fort Collins</city>
        <state>Colorado</state>
        <zip>80528</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Saller</last_name>
      <phone>970-297-6154</phone>
      <email>Jennifer.Saller@uchealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Sarah Tarver</last_name>
      <phone>970-297-6150</phone>
      <email>Sarah.Tarver@uchealth.org</email>
    </contact_backup>
    <investigator>
      <last_name>Steven R Schuster</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SCL Health - St. Mary's Hospital &amp; Medical Center</name>
      <address>
        <city>Grand Junction</city>
        <state>Colorado</state>
        <zip>81501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marty Jacobson</last_name>
      <phone>970-298-1822</phone>
    </contact>
    <investigator>
      <last_name>Kristopher Hansen</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kyle Work</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Miami Cancer Institute at Baptist Health, Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mari Vega</last_name>
      <phone>786-527-8866</phone>
      <email>marive@baptisthealth.net</email>
    </contact>
    <investigator>
      <last_name>Yuliya Linhares</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists - North Region</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph Mace</last_name>
      <phone>727-216-1143</phone>
      <email>jmace@flcancer.com</email>
    </contact>
    <investigator>
      <last_name>Joseph Mace</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Illinois Cancer Care</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61615</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather A Thulean</last_name>
      <phone>309-243-3661</phone>
    </contact>
    <investigator>
      <last_name>Nguyet A Le-Lindqwister</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeremy S Abramson</last_name>
      <phone>617-724-4000</phone>
    </contact>
    <investigator>
      <last_name>Jeremy S Abramson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute / Wayne State University</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nathan DeLuca</last_name>
      <phone>313-576-9689</phone>
    </contact>
    <investigator>
      <last_name>Dahlia Sano</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Leszczynski</last_name>
      <phone>313-916-3590</phone>
    </contact>
    <investigator>
      <last_name>Philip Kuriakose</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ding Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Minnesota Oncology Hematology P.A.</name>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <zip>55435</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megan Hunter</last_name>
      <phone>952-928-2900</phone>
      <email>Megan.hunter@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Steven Rousey</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University in St Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>KC Donaldson</last_name>
      <phone>314-747-1798</phone>
    </contact>
    <investigator>
      <last_name>Nancy Bartlett</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New Jersey Hematology Oncology Associates, LLC</name>
      <address>
        <city>Brick</city>
        <state>New Jersey</state>
        <zip>08724</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Colleen Kats</last_name>
      <phone>516-319-5357</phone>
      <email>ckats@researchcra.com</email>
    </contact>
    <investigator>
      <last_name>Morton Coleman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Regional Cancer Care Associates - Freehold</name>
      <address>
        <city>Freehold</city>
        <state>New Jersey</state>
        <zip>07728</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Colleen Kats</last_name>
      <phone>516-319-5357</phone>
      <email>ckats@researchcra.com</email>
    </contact>
    <investigator>
      <last_name>Morton Coleman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tatyana Feldman</last_name>
      <phone>551-996-5234</phone>
    </contact>
    <investigator>
      <last_name>Tatyana Feldman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Regional Cancer Care Associates - Howell</name>
      <address>
        <city>Howell</city>
        <state>New Jersey</state>
        <zip>07731</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Colleen Kats</last_name>
      <phone>516-319-5357</phone>
      <email>ckats@researchcra.com</email>
    </contact>
    <investigator>
      <last_name>Morton Coleman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Morristown Medical Center/ Carol G. Simon Cancer Center</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07960</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maureen Nowakowski</last_name>
      <phone>973-971-5569</phone>
    </contact>
    <investigator>
      <last_name>Charles M Farber</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Regional Cancer Care Associates - Mount Holly</name>
      <address>
        <city>Mount Holly</city>
        <state>New Jersey</state>
        <zip>08060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Colleen Kats</last_name>
      <phone>516-319-5357</phone>
      <email>ckats@researchcra.com</email>
    </contact>
    <investigator>
      <last_name>Morton Coleman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Regional Cancer Care Associates - Central Jersey</name>
      <address>
        <city>Somerville</city>
        <state>New Jersey</state>
        <zip>08876</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Colleen Kats</last_name>
      <phone>516-319-5357</phone>
      <email>ckats@researchcra.com</email>
    </contact>
    <investigator>
      <last_name>Morton Coleman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Regional Cancer Care Associates - Sparta</name>
      <address>
        <city>Sparta</city>
        <state>New Jersey</state>
        <zip>07871</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>New York Oncology Hematology, P.C.</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Brignull</last_name>
      <phone>518-262-6696</phone>
      <email>susan.brignull@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Mihir Raval</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CareMount Medical Group</name>
      <address>
        <city>Mount Kisco</city>
        <state>New York</state>
        <zip>10549-3412</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Colleen Kats</last_name>
      <phone>516-319-5357</phone>
      <email>ckats@researchcra.com</email>
    </contact>
    <investigator>
      <last_name>Morton Coleman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alayna Santarosa</last_name>
      <phone>646-888-6446</phone>
    </contact>
    <investigator>
      <last_name>David Straus</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Research Alliance - Abraham Mittelman, MD, LLC</name>
      <address>
        <city>Purchase</city>
        <state>New York</state>
        <zip>10577</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Colleen Kats</last_name>
      <phone>516-319-5357</phone>
      <email>ckats@researchcra.com</email>
    </contact>
    <investigator>
      <last_name>Morton Coleman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Research Alliance - Morton Coleman, MD</name>
      <address>
        <city>Westbury</city>
        <state>New York</state>
        <zip>11590</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Colleen Kats</last_name>
      <phone>516-319-5357</phone>
      <email>ckats@researchcra.com</email>
    </contact>
    <investigator>
      <last_name>Morton Coleman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncology Hematology Care</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessa Hubbell</last_name>
      <phone>513-751-2273</phone>
      <email>alessa.hubbell@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Miguel Islas-Ohlmayer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Case Western Reserve University / University Hospitals Cleveland Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Judah Friedman</last_name>
      <phone>440-286-5050</phone>
      <email>judah.friedman@uhhospitals.org</email>
    </contact>
    <investigator>
      <last_name>Judah Friedman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic, The</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deepa Jagadeesh</last_name>
      <phone>216-444-0857</phone>
    </contact>
    <investigator>
      <last_name>Deepa Jagadeesh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Toledo Clinic Cancer Center</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43623</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pam Shoup</last_name>
      <phone>419-214-4236</phone>
      <email>pshoup@toledoclinic.com</email>
    </contact>
    <investigator>
      <last_name>Rex Mowat</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Willamette Valley Cancer Institute/Oncology Assc of Oregon</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Spencer Dandy</last_name>
      <phone>541-741-3451</phone>
      <email>Spencer.Dandy@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Christopher A Yasenchak</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence Portland Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina/Hollings Cancer Center</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian Hess</last_name>
      <phone>843-792-4271</phone>
    </contact>
    <investigator>
      <last_name>Brian Hess</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Tennessee</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Radhakrishnan Ramchandren</last_name>
      <phone>865-305-4893</phone>
      <email>RRamchandren@utmck.edu</email>
    </contact>
    <investigator>
      <last_name>Radhakrishnan Ramchandren</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology - Nashville</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ian W Flinn</last_name>
      <phone>615-329-7274</phone>
      <email>iflinn@tnonc.com</email>
    </contact>
    <investigator>
      <last_name>Ian W Flinn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Austin Midtown</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristen Brueggemann</last_name>
      <phone>512-427-9400</phone>
      <email>kristen.brueggemann@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Jason M Melear</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Medical City Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Flower Mound</name>
      <address>
        <city>Flower Mound</city>
        <state>Texas</state>
        <zip>75028</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Brooke Army Medical Center</name>
      <address>
        <city>Fort Sam Houston</city>
        <state>Texas</state>
        <zip>78234</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew R Peterson</last_name>
      <phone>210-916-6576</phone>
      <email>matthew.r.peterson20.mil@mail.mil</email>
    </contact>
    <investigator>
      <last_name>Matthew R Peterson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Fort Worth 12th Avenue</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fatima Witman</last_name>
      <phone>817-413-1500</phone>
      <email>Fatima.witman@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Asad Dean</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert L Ruxer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center / University of Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hun Ju Lee, MD</last_name>
      <phone>713-745-4367</phone>
      <email>hunlee@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Hun Ju Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - San Antonio Medical Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78240</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alice Bock</last_name>
      <phone>210-595-5355</phone>
      <email>alice.bock@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>John S Renshaw</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Tyler</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shelly K Maxfield</last_name>
      <phone>903-579-9800</phone>
      <email>shelly.maxfield@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Habte A Yimer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute/University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harsh Shah</last_name>
      <phone>801-213-1203</phone>
    </contact>
    <investigator>
      <last_name>Harsh Shah</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists, PC</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristi Ben-Barka</last_name>
      <phone>703-208-3186</phone>
      <email>kristi.ben-barka@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Mitul Gandhi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncology and Hematology Assoc of SW VA DBA Blue Ridge Cancer Care</name>
      <address>
        <city>Salem</city>
        <state>Virginia</state>
        <zip>24153</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Nichols</last_name>
      <phone>540-774-8660</phone>
      <email>jessica.nichols@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Amanda L. Gillespie-Twardy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kadlec Clinic Hematology and Oncology</name>
      <address>
        <city>Kennewick</city>
        <state>Washington</state>
        <zip>99336</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Alderson</last_name>
      <phone>509-783-4637</phone>
      <email>paul.alderson@kadlec.org</email>
    </contact>
    <investigator>
      <last_name>Rangaswamy A Chintapatla</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vista Oncology Inc PS</name>
      <address>
        <city>Olympia</city>
        <state>Washington</state>
        <zip>98506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yun (Lynn) Li</last_name>
      <phone>360-810-3625</phone>
      <email>yun.li@aoncology.com</email>
    </contact>
    <investigator>
      <last_name>Joseph Z Ye</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance / University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1023</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ryan Lynch</last_name>
      <phone>206-606-1739</phone>
    </contact>
    <investigator>
      <last_name>Ryan Lynch</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>Other</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Uwe Hahn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ballarat Regional Integrated Cancer Care</name>
      <address>
        <city>Ballarat</city>
        <state>Other</state>
        <zip>3350</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Geoffrey Chong</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Monash Medical Centre</name>
      <address>
        <city>Clayton</city>
        <state>Other</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Stephen Opat</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Epworth Healthcare</name>
      <address>
        <city>Victoria</city>
        <state>Other</state>
        <zip>3002</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Miles Prince</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Spedali Civili di Brescia</name>
      <address>
        <city>Brescia</city>
        <state>Other</state>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Giuseppe Rossi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <state>Other</state>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Antonio Salar Silvestre, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Blanca Sanchez Gonzalez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Duran i Reynals - Institut Catala d'Oncologia</name>
      <address>
        <city>Barcelona</city>
        <state>Other</state>
        <zip>08908</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Eva Domingo Domenech</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Girona Doctor Josep Trueta</name>
      <address>
        <city>Girona</city>
        <state>Other</state>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jose Maria Roncero Vidal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fundacion Jimenez Diaz</name>
      <address>
        <city>Madrid</city>
        <state>Other</state>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Daniel Morillo Giles</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <state>Other</state>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Antonia Rodriguez Izquierdo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Puerta de Hierro Majadahonda</name>
      <address>
        <city>Majadahonda</city>
        <state>Other</state>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mariano Provencio</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Central de Asturias</name>
      <address>
        <city>Oviedo</city>
        <state>Other</state>
        <zip>33011</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Angel Ramirez Payer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <state>Other</state>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ramon Garcia-Sanz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politecnic La Fe de Valencia</name>
      <address>
        <city>Valencia</city>
        <state>Other</state>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jose Gomez Codina</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 22, 2018</study_first_submitted>
  <study_first_submitted_qc>August 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2018</study_first_posted>
  <last_update_submitted>October 29, 2021</last_update_submitted>
  <last_update_submitted_qc>October 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Brentuximab vedotin</keyword>
  <keyword>Doxorubicin</keyword>
  <keyword>Vinblastine</keyword>
  <keyword>Dacarbazine</keyword>
  <keyword>Nivolumab</keyword>
  <keyword>Seattle Genetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Dacarbazine</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
    <mesh_term>Brentuximab Vedotin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

